Lakefront Biotherapeutics NV - Asset Resilience Ratio
Lakefront Biotherapeutics NV (LKFT) has an Asset Resilience Ratio of 62.77% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read LKFT liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Lakefront Biotherapeutics NV's Asset Resilience Ratio has changed over time. See Lakefront Biotherapeutics NV financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Lakefront Biotherapeutics NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Lakefront Biotherapeutics NV.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.10 Billion | 62.77% |
| Total Liquid Assets | $2.10 Billion | 62.77% |
Asset Resilience Insights
- Very High Liquidity: Lakefront Biotherapeutics NV maintains exceptional liquid asset reserves at 62.77% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Lakefront Biotherapeutics NV Industry Peers by Asset Resilience Ratio
Compare Lakefront Biotherapeutics NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Galecto Inc
NASDAQ:GLTO |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
ABL Bio Inc
KQ:298380 |
Biotechnology | 0.77% |
Annual Asset Resilience Ratio for Lakefront Biotherapeutics NV (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Lakefront Biotherapeutics NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 85.43% | $2.91 Billion | $3.41 Billion | +11.60pp |
| 2024-12-31 | 73.83% | $3.05 Billion | $4.14 Billion | -6.90pp |
| 2023-12-31 | 80.73% | $3.52 Billion | $4.36 Billion | +4.99pp |
| 2022-12-31 | 75.74% | $3.59 Billion | $4.73 Billion | -- |
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more